ReviewAmerican journal of physiology. Lung cellular and molecular physiology2024
Metabolic signatures of acute respiratory distress syndrome: COVID versus non-COVID.
Review in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- The Role of the Respiratory Microbiome in Pneumonia.Clinics in chest medicine · 2026Review
- KL-6 assisted subtyping of ARDS: from subtype-specific metabolomics to LPCAT1 as a pathogenic target.Respiratory research · 2026Article
- Perioperative Blood Biomarkers of Infectious and Non-Infectious Postoperative Pulmonary Complications: A Narrative Review.Journal of clinical medicine · 2026Review
- Plasma phenylalanine is associated with hospital mortality in acute respiratory distress syndrome: a prospective metabolic profiling cohort study.European journal of medical research · 2025Observational
- Lipid metabolism-related genes regulate the immune microenvironment during ex vivo lung perfusion for lung transplants.Journal of thoracic disease · 2025Article
- Advancing omics technologies in acute respiratory distress syndrome: paving the way for personalized medicine.Intensive care medicine experimental · 2025Review
- Decoding immune-metabolic crosstalk in ARDS: a transcriptomic exploration of biomarkers, cellular dynamics, and therapeutic pathways.Frontiers in immunology · 2025Article
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Circulating metabolome as key biomarkers for ventilator-associated pneumonia: Case-Control study in a tertiary care hospital of North India.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Acute respiratory distress syndrome (ARDS) is a fatal pulmonary disorder characterized by severe hypoxia and inflammation. ARDS is commonly triggered by systemic and pulmonary infections, with bacteria and viruses. Notable pathogens include
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.